“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Mesoblast
Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
Mesoblast — 2 videos in collection
Mesoblast is developing adult stem-cell therapies based on its proprietary MPC and MSC platforms. Its lead programmes are in pediatric aGvHD, heart failure, ARDS and lower back pain, all of which are in Phase III or later.
• Please explain what the company does.
• What are mesenchymal stem cells and why they are central to what the company does?
• What is the status of Mesoblast’s trials in difficult conditions such as graft versus host disease (GVHD)?
• Please explain your approach to chronic back pain.
• What are the next steps for these programmes over the next year?
• What is different about your approach to the growing market for heart failure?
• What else can investors expect over the next year?
Get access to the very latest content matched to your personal investment style.
